BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 14707273)

  • 1. Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
    Kreklau EL; Pollok KE; Bailey BJ; Liu N; Hartwell JR; Williams DA; Erickson LC
    Mol Cancer Ther; 2003 Dec; 2(12):1321-9. PubMed ID: 14707273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
    Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL
    Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.
    Ragg S; Xu-Welliver M; Bailey J; D'Souza M; Cooper R; Chandra S; Seshadri R; Pegg AE; Williams DA
    Cancer Res; 2000 Sep; 60(18):5187-95. PubMed ID: 11016647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning.
    Zielske SP; Reese JS; Lingas KT; Donze JR; Gerson SL
    J Clin Invest; 2003 Nov; 112(10):1561-70. PubMed ID: 14617757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Davis BM; Reese JS; Koç ON; Lee K; Schupp JE; Gerson SL
    Cancer Res; 1997 Nov; 57(22):5093-9. PubMed ID: 9371508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G156A MGMT-transduced human mesenchymal stem cells can be selectively enriched by O6-benzylguanine and BCNU.
    Lee K; Gerson SL; Maitra B; Koç ON
    J Hematother Stem Cell Res; 2001 Oct; 10(5):691-701. PubMed ID: 11672516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
    Loktionova NA; Xu-Welliver M; Crone TM; Kanugula S; Pegg AE
    Biochem Pharmacol; 1999 Jul; 58(2):237-44. PubMed ID: 10423163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
    Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
    Phillips WP; Willson JK; Markowitz SD; Zborowska E; Zaidi NH; Liu L; Gordon NH; Gerson SL
    Cancer Res; 1997 Nov; 57(21):4817-23. PubMed ID: 9354444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
    Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
    Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy.
    Davis BM; Roth JC; Liu L; Xu-Welliver M; Pegg AE; Gerson SL
    Hum Gene Ther; 1999 Nov; 10(17):2769-78. PubMed ID: 10584923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells.
    Jansen M; Sorg UR; Ragg S; Flasshove M; Seeber S; Williams DA; Moritz T
    Cancer Gene Ther; 2002 Sep; 9(9):737-46. PubMed ID: 12189523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow.
    Kramer BA; Lemckert FA; Alexander IE; Gunning PW; McCowage GB
    J Gene Med; 2006 Sep; 8(9):1071-85. PubMed ID: 16927363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression.
    Ball CR; Pilz IH; Schmidt M; Fessler S; Williams DA; von Kalle C; Glimm H
    Blood; 2007 Sep; 110(6):1779-87. PubMed ID: 17496202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.
    Kreklau EL; Kurpad C; Williams DA; Erickson LC
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1269-75. PubMed ID: 10565851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SarCNU mediates selection of P140K methylguanine-DNA-methyltransferase transduced human CD34(+) cells in vitro.
    Zielske SP; Gerson SL
    Blood Cells Mol Dis; 2003; 31(1):48-50. PubMed ID: 12850483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro.
    Zielske SP; Gerson SL
    Mol Ther; 2002 Apr; 5(4):381-7. PubMed ID: 11945064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo.
    Marathi UK; Dolan ME; Erickson LC
    Biochem Pharmacol; 1994 Nov; 48(11):2127-34. PubMed ID: 7802703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity.
    Marathi UK; Dolan ME; Erickson LC
    Cancer Res; 1994 Aug; 54(16):4371-5. PubMed ID: 8044784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells.
    Fontes AM; Davis BM; Encell LP; Lingas K; Covas DT; Zago MA; Loeb LA; Pegg AE; Gerson SL
    Mol Cancer Ther; 2006 Jan; 5(1):121-8. PubMed ID: 16432170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.